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Abstract
Breast cancer is by far the most common cancer among women. The heteroge-
neous nature of the onset of this disease has already been proven and a search is 
underway for possible epigenetic mechanisms that affect the course of treatment. 
The indirect immunofluorescence method was used to study the fluorescence 
intensity of histones HP1γ, H3K9me3, H3K27me3, and histone deacetylases SIRT1 
and SIRT6 in dermal fibroblasts of patients with breast cancer and patients at risk 
of developing cancer. The results of the study showed a significant difference in 
the level of fluorescence intensity of histones H3K9me3 and H3K27me3 in the cells 
of patients with breast cancer from the values in the cells of healthy donors. Also, 
the results of the study suggest that the heterochromatin protein HP1γ is a possible 
marker of the heterogeneity of breast cancer.
Keywords: breast cancer, immunofluorescence, HP1γ, H3K9me3, H3K27me3, SIRT1, 
SIRT6
1. Introduction
Despite significant advances in cancer research, breast cancer remains a serious 
problem and, according to WHO, is the most common cancer worldwide affecting 
women. It accounts for 16% of all oncological diseases in women with incidence 
rates of 99.4 per 100,000 women aged 13–90 years. According to forecasts in the 
coming years, its frequency and mortality will increase significantly.
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Modern medicine shows that progress in the fight against breast cancer over the 
past decade is slow. This is not surprising given the important limitations of cur-
rently available targeted treatments. The reasons for the high internal and acquired 
resistance to available target drugs include their temporary antitumor activity and 
the lack of consideration for origins of heterogeneity of tumors. Understanding this 
extremely complex heterogeneity is crucial in the “war” against breast cancer and 
metastasis.
Oncogene activation in mammalian cells leads to proliferative stress and the 
induction of aging, which limits tumor growth. Thus, aging is the physiological 
mechanism of tumor suppression, which prevents progression from benign tumor 
foci to malignant tumors. Induction of aging by oncogene activation is called 
oncogene-induced senescence, OIS. Oncogene inactivation, on the other hand, can 
also cause aging. MYC inactivation causes cell aging, and regression in various tumor 
samples, such as lymphoma, osteosarcoma, and hepatocellular carcinoma (HCC) [1].
Recently, researchers have been interested in breast cancer in young women. 
Current evidence suggests that in women under the age of 45, breast cancer is 
undoubtedly the main cause of cancer mortality. This type of cancer is most likely 
very heterogeneous and has potentially aggressive and complex biological features. 
However, management strategies, recommendations, and options are not based 
on age, and the “complex” biology of this type of cancer remains uncertain and 
unexplored [2].
Recent studies suggest a significant association between biological aging and 
objective cognitive performance in breast cancer survivors. Future prospective 
studies are needed to confirm the causative role of biological aging as a driver of 
cognitive decline after cancer treatment [3].
To study the processes of activation of cell aging in tumor cells, it is important to 
understand the effect of chromatin structure on cell proliferation, aging of cells and 
tissues, and the treatment of cancer. The foci of heterochromatin associated with 
aging (SAHF) are specialized domains of facultative heterochromatin that form in 
aging human cells. Although SAHFs are highly densified domains of heterochro-
matin, they largely exclude other chromatin domains in telomeres and pericentro-
meres, which are themselves believed to be heterochromatic.
HP1 proteins are important components of a dynamic nuclear response that 
detects and eliminates defects in the epigenetic information encoded in chroma-
tin through histone modifications and DNA methylation. Defects in this “chro-
matin repair” response in transformed cells can contribute to the preferential 
killing of cancer cells using cancer epigenetic therapy, which is still under clinical 
development [4].
In breast cancer, the level of the H3K27me3 protein rises to maintain the LOX 
gene in a repressed state [5]. The global level of H3K9me3 protein, on the contrary, 
decreases during transformation, and its distribution over chromatin is repro-
grammed. Perhaps, this is due to the mechanism of the occurrence of breast cancer 
by regulating gene expression and chromatin stability during cell transformation 
[6]. Epigenetic modifications of the H3K9me3 and H3K27me3 histones may be 
useful as diagnostic/prognostic biomarkers and/or therapeutic targets for breast 
cancer, since DNA and histone modifications are involved in the activation of PD-1, 
CTLA-4, TIM-3, and LAG-3 in tissue of breast tumors [7, 8].
The intratumoral heterogeneity due to the presence of cancer stem cells 
(cancer stem cell [CSC]) is the main cause of drug resistance and distant 
metastases of breast cancer. Histone deacetylase SIRT1 outlines a central role 
in the regulation of CSC and the SIRT1 pathway can be a promising therapeutic 
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strategy [9, 10]. Overexpression of SIRT1 significantly stimulates breast can-
cer growth both in vitro and in vivo, while SIRT1 knockdown inhibits cancer 
phenotypes [11]. Also, histone deacetylase SIRT6 may be a therapeutic marker. 
Sirtuin 6 (SIRT6) is associated with longevity and is also a tumor suppressor. 
The survival of patients with breast cancer was positively correlated with the 
abundance of SIRT6 and inversely correlated with phosphorylation of SIRT6 at 
Ser (338) [12]. SIRT1 and SIRT6 play a role in fine-tuning the acetylation of the 
antitumor suppressor FOXO3 (Forkhead Box O3) and sensitivity to lapatinib. 
The results of immunohistochemistry for different subtypes of breast cancer 
showed that the high levels of SIRT6/1 are associated with constant high expres-
sion of FOXO3, which in turn is associated with deregulation/inactivation of 
FOXO3 and a poor prognosis of the course of the disease [13].
2. Material and methods
2.1 Study group selection
We studied three groups:
1. Patients with breast cancer: two patients 30 (BC30SP1) and 55 (BC55SP1) 
years old.
2. Breast cancer risk group: a 30-year-old person with 5382insC mutation in the 
BRCA1 gene (BRCA1SP) and two mothers of patients with ataxia-telangiecta-
sia—47 (AT8SP) and 45 (AT9SP) years old. Heterozygous carriers of mutations 
in the ATM gene are at risk of tumors, including breast cancer [14].
3. Healthy donors: two donors without breast cancer or a history of oncological 
diseases of 30 (N9SP) and 55 (FK19) years old.
2.2 Cell line production
Cell lines of dermal fibroblasts were obtained by the migration method from 
post-operative material. Lines of dermal fibroblasts BRCA1SP, BC30SP1, and 
BC55SP1 were obtained from a skin biopsy, which was performed under local 
anesthesia. Skin biopsies were placed in Petri dishes, filled with complete MEM 
growth medium (Gibco, USA) containing 15% bovine fetal serum (Gibco, USA), 
100 IU/ml penicillin, 100 μg/ml streptomycin (Gibco, USA), 25 μg/ml fungicon, 
0.3 mg/ml L-glutamine, and cultured in a CO2 incubator at +37°C in an atmo-
sphere with 5% CO2 until a subconfluent monolayer was obtained. Next, the cells 
were rinsed with a solution of phosphate-buffered saline (PBS), removed from 
Petri dishes using 0.25% Trypsin-Versene solution (Gibco, USA) and scattered on 
coverslips (Carl Zeiss, Germany).
2.3 Immunocytochemical analysis
By indirect immunofluorescence method, the cell lines were stained with anti-
bodies to chromatin proteins HP1γ, H3K9me3, H3K27me3, and histone deacetylases 
SIRT1 and SIRT6.
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According to the standard protocol and usage annotations of antibodies, the 
cells were fixed on ice with a 4% formaldehyde solution for 10 minutes at +40°С 
followed by fixation with ice-cold 70% ethanol solution in PBS (15 min at room 
temperature), washed with a solution of PBS, permeabilized with a 1.5% X-100 
triton solution in PBS (15 min at room temperature), washed with a PBS solution 3 
times for 5 minutes, and incubated in a blocking solution of 5% BSA in PBS (1 h at 
room temperature), followed by washing with PBS. As the first antibodies, mouse 
IgG to H3K9me3, H3K27me3, and SIRT1 (Cell Signaling, UK) and rabbit IgG to the 
HP1γ protein (Abcam, UK), H3K27me3, SIRT6, and SIRT7 (Cell Signaling, UK) 
were used. Goat antibodies against mouse or rabbit IgG conjugated with Alexa 
Fluor 488 and 546 (Invitrogen, USA) at a 1: 500 dilution were used as the second 
antibodies. To prevent the rapid burnout of immunofluorescence dyes, the prepara-
tions were enclosed in antifading using SlowFade Gold Antifade reagent with DAPI 
(Invitrogen, USA).
2.4 Microscopy
Images from stained preparations were obtained using an AXIOVERT200-
DFC420 fluorescent inverted microscope (Carl Zeiss AG, Germany) equipped with 
a Leica DFC 420 camera and an E×40/0.75 lens. In each line, using the Fiji program, 
fluorescence intensity in 100 cells was determined.
2.5 Statistical analysis
For the parameter of statistical analysis, the standard deviation of the mean 
values was chosen. Statistical analysis was performed in Google Sheets and Excel.
3. Results
The fluorescence intensity of chromatin proteins HP1γ, H3K9me3, H3K27me3, 
and histone deacetylases SIRT1 and SIRT6 was measured in the studied lines 
(Figure 1).
During the fluorescence intensity analysis, we studied both average intensity 
and intensity distribution. Intensity distribution in all cell lines was visualized with 
histograms plotted in Google Sheets in two ways:
• with automatic bin size selection
• with manual bin size selection—5 RFU, chosen empirically.
Histograms of the distribution of fluorescence intensities make it possible to 
assess how heterogeneous the cell line is for the studied protein and also to detect 
the presence of several subpopulations in cell lines.
Overlapping histograms of the fluorescence intensities of different cell lines 
with the same bin size allows comparing the distribution of the same protein in 
different cell lines.
3.1 HP1γ fluorescence intensity
The highest value of the average HP1γ fluorescence intensity was detected 
in dermal fibroblasts of the 30-year-old patient with breast cancer, and it was 
8.25 times higher than that of the 55-year-old patient with breast cancer, 3.5 
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Figure 1. 
Immunocytochemical analysis of the studied lines.
Figure 2. 
Average fluorescence intensity of HP1γ in the nuclei of dermal fibroblasts of the studied lines.
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times more than that of a patient at risk with a mutation in the BRCA1 gene—
BRCA1SP; 6.7 and 6.3 times more than mothers of patients with AT (AT9SP and 
AT8SP) (Figure 2). Such difference in the values of HP1γ fluorescence intensity 
can be explained by the fact that the histone heterochromatin protein HP1γ is 
considered a marker of aging and its amount decreases in the cell with age. In 
addition, the nature of the cancer of a 30-year-old patient, most probably, is 
different than that of a 55-year-old patient.
The average fluorescence intensity levels of HP1γ in healthy donors did not 
significantly differ from each other, despite the fact that the data differed by a 
factor of 6.1 and 13.5 RFU in lines N9SP and FK19, respectively. A significant 
difference in the average HP1γ fluorescence intensity of the BS30SP1 line was 
observed only in relation to the line of one healthy N9SP donor and was 5.4 
times greater.
The absence of a significant difference between the cells of healthy donors is 
explained by the large value of the standard deviation in the population of lines due 
to the large spread of data.
Figure 3. 
Histograms of fluorescence intensity distribution of HP1γ.
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The histogram of the distribution of HP1γ fluorescence intensities (Figure 3) 
in the cell lines showed the presence of two subpopulations in the BC55SP1 
and BRCA1SP lines, each with its own distribution. In the 55-year-old healthy 
donor line, the boundary between the two subpopulations was less pronounced. 
Perhaps, this is due to age-related epigenetic changes in the HP1γ protein. In 
the remaining lines, insignificant second intensity peaks in some cells were 
observed, which may be associated with some rare cell changes. Interestingly, the 
picture of the distribution of HP1γ fluorescence intensity in patients with breast 
cancer differed from each other, as did the values of the average intensity.
When overlapping the histograms of HP1γ fluorescence intensity distribution 
in different cell lines with the same bin size, one can see how widely the HP1γ 
Figure 4. 
Overlapping histograms of the distribution of fluorescence intensities of HP1γ, H3K27me3, and H3K9me3 in the 
studied lines with bin size of 5 RFU.
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fluorescence intensities were distributed in the BC30SP1 line, in contrast to 
other lines (Figure 4).
3.2 Fluorescence intensity of H3K9me3 and H3K27me3
The average fluorescence intensity levels of H3K9me3 and H3K27me3 in the 
dermal fibroblast lines of patients with breast cancer significantly differed from 
the levels in the cells of healthy donors (Figure 5). The average levels of H3K9me3 
fluorescence intensity in the dermal fibroblast lines BC30SP1 and BC55SP1 virtually 
did not differ from each other (15.2 and 17.6 RFU) and were significantly lower by 5 
and 4 times than the values of healthy donors 30 and 55 years old, respectively, for 
which these indicators were the highest. Interestingly, in the cells of the BRCA1 gene 
mutation’s carrier, the average value of the H3K9me3 fluorescence intensity was 
significantly 3 times higher than in the cells of patients with breast cancer, although 
the data in the cells of mothers of patients with AT did not significantly differ from 
patients with breast cancer.
Histograms of the distribution of fluorescence intensities of H3K27me3 and 
H3K9me3 did not reveal two cell subpopulations in any of the studied lines. In 
all lines, insignificant second peaks of fluorescence intensities were observed 
(Figures 6 and 7). The distribution of fluorescence intensities of H3K27me3 and 
H3K9me3 revealed something similar to two subpopulations, but with very blurred 
boundaries. This picture may possibly be associated with age-related epigenetic 
changes in the cell.
When overlapping the histograms of H3K27me3 and H3K9me3 fluorescence 
intensity distribution in different cell lines with the same bin size, it can be seen that 
all lines have a sufficiently wide range of fluorescence intensities of H3K27me3 and 
H3K9me3, except for the BC30SP1 line, which has a fairly narrow range of fluores-
cence intensities of H3K27me3. This fact suggests a greater sensitivity of H3K27me3 
and H3K9me3 histones to the state of the cell (cell cycle, apoptosis, ptosis, etc.). The 
widest distribution of fluorescence intensities was shown in the BRSA1SP, AT8MSP, 
and N9SP lines (Figure 4).
Figure 5. 
Average fluorescence intensity of H3K27me3 and H3K9me3 in the nuclei of dermal fibroblasts of the studied 
lines.
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3.3 Fluorescence intensity of SIRT1 and SIRT6
The average fluorescence intensity levels of SIRT1 (Figure 8) in patients with 
breast cancer did not significantly differ from the levels in the lines of healthy 
donors, carriers of the mutations in the BRCA1 gene, and the mother of one patient 
with AT. However, the average SIRT1 fluorescence intensity in the line of the second 
mother of the patient with AT was significantly 13 times higher than in the lines of 
patients with breast cancer.
The average fluorescence intensity levels of SIRT6 were also the lowest in the 
lines of patients with breast cancer and patients with a mutation in the BRCA1 
Figure 6. 
Histograms of fluorescence intensity distribution of H3K27me3.
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Figure 7. 
Histograms of fluorescence intensity distribution of H3K9me3.
Figure 8. 
Average fluorescence intensity of SIRT1 and SIRT6 in the nuclei of dermal fibroblasts of the studied lines.
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gene. Significantly, the levels of the average fluorescence intensity in the lines 
of patients with breast cancer did not differ from the levels of healthy donors, 
while they were significantly lower by 5 and 18 times the values in the lines of 
mothers of patients with AT.
Analysis of the histograms of the distribution of the fluorescence intensities of 
SIRT6 (Figure 9) and SIRT1 (Figure 10) in cell lines revealed two subpopulations 
with different distributions in the AT8MSP line according to the SIRT6 fluorescence 
intensity and in the AT9MSP line according to the SIRT1 fluorescence intensity. 
In the N9SP and FK19 cell lines, several significant peaks in SIRT6 fluorescence 
intensity were observed.
When overlapping histograms of SIRT6 and SIRT1 fluorescence intensity 
distributions in different cell lines with the same bin size, it is possible to 
observe that the widest range of SIRT6 fluorescence intensity is in the AT8MSP 
cell line and that of SIRT1 fluorescence intensity is in the AT9MSP cell line 
(Figure 11).
Figure 9. 
Histograms of fluorescence intensity distribution of SIRT6.
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4. Conclusions
Modulation of chromatin structure through modification of histones is the main 
epigenetic mechanism and regulator of gene expression. However, the contribu-
tion of chromatin properties to the heterogeneity and evolution of tumors remains 
unknown. Epigenetic labels are critical regulators of chromatin and gene activity. 
Their role in normal physiology and pathological conditions, including the develop-
ment of cancer, is still unclear.
High expression of immune control points in the tumor microenvironment 
plays an important role in suppressing antitumor immunity, which is associated 
with poor prognosis and cancer progression. Major epigenetic modifications of 
both DNA and histone may be involved in the activation of immune control points 
in cancer.
Of course, for a more accurate study of epigenetic differences and features in 
breast cancer, a wider sample of the studied groups is needed. However, our results 
allow us to draw some preliminary conclusions in this matter. The results of our 
work showed significant differences in the lines of patients with breast cancer from 
the values of healthy donors only in terms of the average fluorescence intensity 
of H3K9me3 and H3K27me3. Contrary to published data, the average value of 
Figure 10. 
Histograms of fluorescence intensity distribution of SIRT1.
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H3K27me3 fluorescence intensity in the cells of patients with breast cancer was 
significantly lower than in cells of healthy donors. Most likely, this is due to the fact 
that the study was not carried out in tumor cells.
Significant differences between the lines of patients with breast cancer were 
observed only in the values of the average intensity of HP1γ. The average HP1γ 
fluorescence intensity in a patient with breast cancer of 30 years was the largest of 
all the studied lines and in a patient with breast cancer of 55 years the lowest. The 
HP1γ fluorescence intensity in the line of 30 years old breast cancer patient was 8.25 
times higher than in the line of 55 years old patient. Our results suggest that hetero-
chromatin protein is a potential marker for breast cancer.
Thus, our results confirmed data on changes in the amount of H3K9me3 and 
H3K27me3 proteins in breast cancer.
An analysis of histograms of fluorescence intensity distribution of HP1γ, 
H3K27me3, H3K9me3, SIRT1, and SIRT6 allowed us to see how differently the 
fluorescence intensities are distributed in the cell lines and also allowed us to distin-
guish two cell lines with two subpopulations of the fluorescence intensity of HP1γ 
(BC55SP1 and BRSASP1). However, for other cell markers, two subpopulations in 
this line were not detected. A second minor peak in HP1γ fluorescence intensity was 
detected in the BC30SP1 cell line, but the distribution pattern was different from 
the distribution in the BC55SP1 line.
Interestingly, a pattern of fluorescence intensity distribution differed in different 
lines. But in most cases, it was similar within the same cell line in terms of fluores-
cence intensities of the HP1γ, H3K27me3, H3K9me3, SIRT1, and SIRT6 proteins.
Usage of average fluorescence intensity value as a single characteristic is not suf-
ficient to properly compare different cell lines, because it masks significant varia-
tions in fluorescence intensity distribution. Overlapping histograms of fluorescence 
Figure 11. 
Overlapping histograms of the distribution of fluorescence intensities of SIRT1 and SIRT6 in the studied lines 
with bin size of 5 RFU.
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intensity distribution make it possible to assess variability of a given protein in a 
population.
The broadest range of fluorescence intensity values was demonstrated by the 
BRCA1SP (HP1γ fluorescence intensity), AT8SP (SIRT6 fluorescence intensity), 
and AT9SP (SIRT1 fluorescence intensity) lines.
But on average, across all cell lines, the broadest range of fluorescence intensity 
values was shown by histones H3K27me3 and H3K9me3. The data obtained suggest 
that these proteins are more “sensitive” to the state of the cell during normal life 
cycle and during pathological changes.
Thus, our results confirm changes in the amount of H3K9me3 and H3K27me3 
proteins in breast cancer.
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